HC Wainwright & Co. Maintains Buy on Aethlon Medical, Lowers Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino maintains a 'Buy' rating on Aethlon Medical (NASDAQ:AEMD), but has lowered the price target from $90 to $23.
October 24, 2023 | 5:57 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target, HC Wainwright & Co. maintains a 'Buy' rating on Aethlon Medical, indicating continued confidence in the company's prospects.
The lowered price target may initially cause some investor concern, potentially leading to short-term volatility in AEMD's stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could balance out any negative impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100